Anti-FLT4 Antibody (Rabbit Polyclonal antibody) General Information
Reacts with: Human
Recombinant Human VEGFR3 protein (Catalog#10806-H08H)
Produced in rabbits immunized with purified, recombinant Human VEGFR3 / FLT4 extracellular domain (rhVEGFR3; Catalog#10806-H08H; Met 1-Ile 776; NP_002011.2). Total IgG was purified by Protein A affinity chromatography.
Polyclonal Rabbit IgG
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Anti-FLT4 Antibody (Rabbit Polyclonal antibody) Validated Applications
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-FLT4 Antibody Alternative Names
Anti-FLT-4 Antibody;Anti-FLT-41 Antibody;Anti-FLT41 Antibody;Anti-LMPH1A Antibody;Anti-PCL Antibody;Anti-VEGF Receptor 3 Antibody;Anti-VEGFR-3 Antibody;Anti-VEGFR3 Antibody
FLT4 Background Information
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.
Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
fms related tyrosine kinase 4
Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52. Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36. Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5. Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.